LETTER
We were very interested to read the minireview by Boyd et al. (1) on the classification, identification, epidemiology, and treatment of OXA-48-like carbapenemase-producing Enterobacterales. In their discussion of cefiderocol, the authors were correct to point out “it is unclear how many patients had OXA-48-like producers” with regard to the CREDIBLE-CR study (2). Aside from a single poster describing the outcomes of specific carbapenemases from the CREDIBLE-CR study (3), we have not published data specific to clinical efficacy in OXA-48-producing infections except for two cases of bacteremia (4). The authors also point out that registrational clinical trials that usually exclude patients with known carbapenem-resistant infections due to the inactivity of the control antibiotics provide limited high-quality information pertaining to molecularly characterized clinical data on OXA-48- and OXA-48-like pathogens.
Shionogi reviewed both the CREDIBLE-CR and APEKS-NP (5) clinical trial databases, where all pathogens were molecularly characterized. A total of 10 patients with OXA-48-positive Enterobacterales who received cefiderocol were identified (Table 1). Seven were from CREDIBLE-CR, and three were from APEKS-NP. All characterized pathogens were Klebsiella pneumoniae species. Of note, three contained OXA-48 along with NDM-1 carbapenemase, and all contained other extended-spectrum (ESBL) and original-spectrum (OSBL) type beta-lactamases. All but two isolates had high-level resistance to meropenem (MIC > 8 μg/mL). All patients but one received cefiderocol as monotherapy, 7 of 10 (70%) patients were judged to have clinical cure at the test-of-cure assessment (cefiderocol MIC range, 0.12 to 4 mg/L), and all survived through day 28.
TABLE 1.
Summary of CREDIBLE-CR and APEKS-NP database results for Klebsiella pneumoniae
| Clinical study | Cefiderocol MIC (μg/mL) | Meropenem MIC (μg/mL) | Site of infectiona | Country | Clinical outcome at TOC | Beta-lactamase profileb |
|---|---|---|---|---|---|---|
| CREDIBLE-CR | 2 | 4 | BSI/sepsis | Spain | Clinical failure | CTX-M-15; SHV-OSBL; TEM-OSBL; OXA-48 |
| 4 | >64 | cUTI | Turkey | Clinical cure | CTX-M-15; SHV-OSBL; TEM-OSBL; OXA-48; NDM-1 | |
| 0.12 | 32 | cUTI | Turkey | Clinical cure | CTX-M-9-group; SHV-OSBL; TEM-OSBL; OXA-48 | |
| 1 | 16 | cUTI | Turkey | Clinical cure | CTX-M-15; SHV-OSBL; TEM-OSBL; OXA-232 | |
| 1 | 8 | cUTI | Turkey | Clinical cure | CTX-M-15; SHV-OSBL; TEM-OSBL; OXA-48 | |
| 4 | >64 | cUTI | Korea | Indeterminate | CTX-M-55; SHV-OSBL; OXA-232; NDM-1 | |
| 1 | >64 | BSI/sepsis | Thailand | Clinical cure | CTX-M-15; SHV-OSBL; TEM-OSBL; OXA-232; NDM-1 | |
| APEKS-NP | 2 | 64 | RTI | Ukraine | Clinical cure | CTX-M-1-TYPE; SHV-OSBL; TEM-OSBL; OXA-48 |
| 1 | 64 | RTI | Russia | Clinical cure | CTX-M-15; SHV-OSBL; OXA-48 | |
| 0.5 | 32 | RTI | Georgia | Indeterminate | CTX-M-15; SHV-OSBL; TEM-OSBL; OXA-48 |
BSI, bloodstream infection; cUTI, complicated urinary tract infection; RTI, respiratory tract infection.
Beta-lactamases in bold type are carbapenemases.
Although these numbers are small, the clinical and microbiological outcomes were consistent with the studies’ overall findings of efficacy against Enterobacterales. Together with the demonstrated in vitro stability of cefiderocol to OXA-48 hydrolysis (6) and the in vitro activity against OXA-48 producers (7–9), we are confident of the potential benefit of cefiderocol treatment for OXA-48-producing Enterobacterales.
ACKNOWLEDGMENTS
This letter was supported by Shionogi & Co., Ltd.
We are all employees of Shionogi, the marketing authorization holder for cefiderocol.
Footnotes
For the article discussed, see https://doi.org/10.1128/AAC.00216-22.
The authors of the published article did not feel that a response was necessary.
REFERENCES
- 1.Boyd SE, Holmes A, Peck R, Livermore DM, Hope W. 2022. OXA-48-like β-lactamases: global epidemiology, treatment options, and development pipeline. Antimicrob Agents Chemother 66:e00216-22. doi: 10.1128/aac.00216-22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. 2021. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21:226–240. doi: 10.1016/S1473-3099(20)30796-9. [DOI] [PubMed] [Google Scholar]
- 3.Longshaw C, Santerre Henriksen A, Bain M, Matsunaga Y. 2020. Post-hoc analysis of the clinical and microbiological outcomes for cefiderocol against carbapenem resistant Enterobacterales in the CREDIBLE-CR study, poster. BSAC Gram-Negative Conference. Presented as poster at BSAC conference ‘Into clinical practice: Meeting the challenges of Gram-negative infection management’, Virtual, 14 October 2020.
- 4.Paterson DL, Kinoshita M, Baba T, Echols R, Portsmouth S. 2022. Outcomes with cefiderocol treatment in patients with bacteraemia enrolled into prospective phase 2 and phase 3 randomised clinical studies. Infect Dis Ther 11:853–870. doi: 10.1007/s40121-022-00598-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit J-F, Zeitlinger M, Nagata TD. 2021. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21:213–225. doi: 10.1016/S1473-3099(20)30731-3. [DOI] [PubMed] [Google Scholar]
- 6.Poirel L, Kieffer N, Nordmann P. 2018. Stability of cefiderocol against clinically significant broad-spectrum oxacillinases. Int J Antimicrob Agents 52:866–867. doi: 10.1016/j.ijantimicag.2018.11.005. [DOI] [PubMed] [Google Scholar]
- 7.Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. 2017. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis 36:2319–2327. doi: 10.1007/s10096-017-3063-z. [DOI] [PubMed] [Google Scholar]
- 8.Takemura M, Wise M, Hackle M, Sahm D, Echols R, Yamano Y. 2022. Cefiderocol susceptibility against molecularly characterized carbapenemase-producing Enterobacterales in North America and Europe between 2014 and 2019: SIDERO-WT-2014–2019 studies, abstr 696. 32nd ECCMID, Lisbon, Portugal.
- 9.Delgado-Valverde M, Conejo MDC, Serrano L, Fernández-Cuenca F, Pascual Á. 2020. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 75:1840–1849. doi: 10.1093/jac/dkaa117. [DOI] [PMC free article] [PubMed] [Google Scholar]